Related Experiment Video

Updated: Jan 10, 2026

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
09:03

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

647

Liver cancer: still a long way to go

Jordi Bruix

    Hepatology (Baltimore, Md.)
    |June 29, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
    12:24

    A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

    Published on: September 30, 2021

    5.9K
    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
    06:38

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

    Published on: September 12, 2019

    9.4K

    Related Experiment Videos

    Last Updated: Jan 10, 2026

    Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
    09:03

    Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

    Published on: January 26, 2024

    647
    A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
    12:24

    A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

    Published on: September 30, 2021

    5.9K
    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
    06:38

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

    Published on: September 12, 2019

    9.4K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    8.6K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.6K
    Diseases of the Liver and Gallbladder01:26

    Diseases of the Liver and Gallbladder

    1.8K
    Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
    Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
    1.8K

    Articles linked to this work by shared authors, journal, and citation graph.

    Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

    Alimentary pharmacology & therapeutics·2026

    BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update.

    Journal of hepatology·2025

    Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.

    Journal of hepatology·2025

    Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association.

    The Lancet regional health. Europe·2025

    Diagnostic performance of contrast-enhanced US in small liver nodules not conclusively characterized after MRI in cirrhotic patients.

    European radiology·2025

    Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer risk.

    BMC gastroenterology·2025

    Genetic regulation of CPEB3-mediated alternative polyadenylation associated with survival of patients with hepatocellular carcinoma.

    Hepatology (Baltimore, Md.)·2026

    Beyond cirrhosis: Major adverse liver outcomes across homozygous and heterozygous Alpha-1 antitrypsin deficiency associated liver disease.

    Hepatology (Baltimore, Md.)·2026

    Shear wave elastography demonstrates similar risk stratification performance to vibration-controlled transient elastography in FIB-4-based two-step algorithms for MASLD.

    Hepatology (Baltimore, Md.)·2026

    A First-in-Human study of AHB-137, an unconjugated antisense oligonucleotide, in healthy subjects and patients with chronic hepatitis B.

    Hepatology (Baltimore, Md.)·2026

    Hepatocyte hnRNPK preserves mitochondrial integrity to restrain liver injury and fibrosis.

    Hepatology (Baltimore, Md.)·2026

    Liver-on-a-Chip: Applications for clinical modeling of liver disease using microscale systems.

    Hepatology (Baltimore, Md.)·2026

    Exercise interventions remodel the aging microenvironment to improve prognosis in older patients with cancer.

    Frontiers in immunology·2026

    Dynamic junction remodeling and transient vascular disruption during cancer cell extravasation across the blood-brain barrier.

    Frontiers in cell and developmental biology·2026

    RUNX3+ basal-like malignant cells: architects of an immunosuppressive microenvironment in bladder cancer: a comprehensive bioinformatics analysis of single-cell and spatial transcriptomics.

    International journal of surgery (London, England)·2026

    CPT1A through succinylation regulates the CTCF/LINC01503‒91aa feedback loop to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.

    Clinical and translational medicine·2026

    CDK4/6 Inhibitors in the Management of Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations.

    Asia-Pacific journal of clinical oncology·2026

    Closing the gap in aging science: unlocking the potential of nanoparticles in senescence therapy.

    Biogerontology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us